I don't normally comment in RMD threads, as I have faith in the company thus only reviewing its performance every HY.
To be fair, I think both madamswer & wolbellee raised good points.
I am a dealer of Resmed product in my pharmacy. Recently a public health professor from a university approached me to start a pilot program that can help me diagnose & also manage the patients with chronic sleep apnoea. We are designing a cloud-based software that can enable the data is shared between patient, me and the sleep clinic. Therefore a IT software has its role (& of course market demand) in sleep apnoea area. I agree with Wolbellee that it makes sense for RMD to dip into IT industry to expand its revenue.
However from RMD perspective, rather than designing a software by itself to tailor to its need (or to outsource it to a reputable IT company), it actually acquires the whole IT company which includes a big chunk of goodwill & several other revenues irrelevant to sleep apnoea industry. I agree with Madamswer that RMD may be better off acquiring the patent of the software (or leasing the patent on a long-term contracts), if not outsourcing the IT tasks to a reputable company)
I appreciate both your posts, and I hope both of you can discuss to reach an agreement in a constructive way to provide informative benefits to all HC readers.
Cheers guys.
RMD Price at posting:
$8.10 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)